Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | 48.8% | 195.8% | -80% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $1 |
| % Margin | 100% | 99.6% | 98.8% | 97.8% |
| R&D Expenses | $4 | $5 | $7 | $7 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | -$0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $8 | $11 | $11 |
| Operating Income | -$8 | -$8 | -$11 | -$10 |
| % Margin | -1,052.3% | -1,603.1% | -6,583% | -1,211.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$7 | -$8 | -$10 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$8 | -$10 | -$9 |
| % Margin | -1,028.5% | -1,547.3% | -6,327.9% | -1,144.9% |
| EPS | -0.9 | -0.93 | -1.29 | -1.17 |
| % Growth | 3.2% | 27.9% | -10.3% | – |
| EPS Diluted | -0.9 | -0.93 | -1.29 | -1.17 |
| Weighted Avg Shares Out | 8 | 8 | 8 | 8 |
| Weighted Avg Shares Out Dil | 8 | 8 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$11 | -$10 |
| % Margin | -1,052.3% | -1,602.7% | -6,581.8% | -1,209% |